Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Efficacy of combined PD-1 immune therapy and chemotherapy in the treatment of locally advanced non-small cell lung cancer

Yongjie Li, Dunzhi Fu, Biao Li, Yuan Zhou, Fan Li, Qiongyu Wang, Jialei Huang

Department of Thoracic Surgery, The Second Affiliated Hospital of Hainan Medical University, Haikou, China;

For correspondence:- Jialei Huang Email: HuangJL1668@163.com Tel:+8618808931668

Accepted: 27 April 2023 Published: 30 May 2023

Citation: Li Y, Fu D, Li B, Zhou Y, Li F, Wang Q, et al. Efficacy of combined PD-1 immune therapy and chemotherapy in the treatment of locally advanced non-small cell lung cancer. Trop J Pharm Res 2023; 22(5):1065-1071 doi: 10.4314/tjpr.v22i5.19

© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the clinical efficacy of anti-programmed cell death-1 (PD-1) immunotherapy in combination with chemotherapy in patients suffering from locally advanced non-small cell lung cancer (NSCLC).

Methods: A total of 110 NSCLC patients admitted in The Second Affiliated Hospital of Hainan Medical University, Haikou, China were randomly divided into two groups using envelope method. The control group was administered pemetrexed and cisplatin, and the study group was further treated with nivolumab. Each treatment cycle lasted for 21 days, and a total of 6 cycles were administered for the duration of therapy. The short-term objective response rate, adverse reactions, programmed cell death-5 (PDCD-5), tumor necrosis factor-α (TNF-α), tumor necrosis factor-β1 (TGF-β1), and immune status indices were determined.

Results: The objective remission rate in study group was 79.25 % (42/53), which was higher than that in control group (61.40 %, 35/57; p < 0.05). After treatment, both groups showed higher levels of PDCD-5 and TNF-α compared to their pre-treatment values, while demonstrating lower levels of TGF-β1. Furthermore, PDCD-5 and TNF-α in study group were higher than those in control group, while TGF-β1 was lower than that in control group (p < 0.05). In control group, the values of clusters of differentiation 3+(CD3+), 4+(CD4+), and 8+(CD8+) decreased after treatment, while the values of CD8+ increased after treatment. The CD3+, CD4+, and CD4+/CD8+ in study group were higher than those in control group, while CD8+ was lower than those in control group (p < 0.05).

Conclusion: Anti-PD-1 immunotherapy combination with chemotherapy in the treatment of local NSCLC stabilizes the immune system and improves the short-term efficacy of patients with advanced NSCLC. Further clinical trials are, however, required prior to application of this combination clinical practice

Keywords: Programmed cell death-1, Chemotherapy, Non-small cell lung cancer, Late stage, Curative effect, Immune state